Trial LEP-F1 + GLA-SE in Healthy Adult in Areas Endemic for Leprosy
Status:
NOT_YET_RECRUITING
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
This is a phase 1b, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety, tolerability, and immunogenicity of LEP-F1 + GLA-SE compared to placebo administered as three intramuscular (IM) injections in adult participants aged 18 to 55.
Phase:
PHASE1
Details
Lead Sponsor:
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)